TET2-mediated epigenetic reprogramming of breast cancer cells impairs lysosome biogenesis - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Life Science Alliance Année : 2022

TET2-mediated epigenetic reprogramming of breast cancer cells impairs lysosome biogenesis

Résumé

Methylation and demethylation of cytosines in DNA are believed to act as keystones of cell-specific gene expression by controlling the chromatin structure and accessibility to transcription factors. Cancer cells have their own transcriptional programs, and we sought to alter such a cancer-specific program by enforcing expression of the catalytic domain (CD) of the methylcytosine dioxygenase TET2 in breast cancer cells. The TET2 CD decreased the tumorigenic potential of cancer cells through both activation and repression of a repertoire of genes that, interestingly, differed in part from the one observed upon treatment with the hypomethylating agent decitabine. In addition to promoting the establishment of an antiviral state, TET2 activated 5mC turnover at thousands of MYC-binding motifs and down-regulated a panel of known MYC-repressed genes involved in lysosome biogenesis and function. Thus, an extensive cross-talk between TET2 and the oncogenic transcription factor MYC establishes a lysosomal storage disease-like state that contributes to an exacerbated sensitivity to autophagy inducers.
Fichier principal
Vignette du fichier
e202101283.full.pdf (3.26 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03630016 , version 1 (04-04-2022)

Licence

Paternité

Identifiants

Citer

Audrey Laurent, Thierry Madigou, Maud Bizot, Marion Turpin, Gaëlle Palierne, et al.. TET2-mediated epigenetic reprogramming of breast cancer cells impairs lysosome biogenesis. Life Science Alliance, 2022, 5 (7), pp.e202101283. ⟨10.26508/lsa.202101283⟩. ⟨hal-03630016⟩
16 Consultations
41 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More